NEW YORK (GenomeWeb News) – EMD Millipore today announced a clinical research, licensing, and joint development deal with Japan's Sysmex aimed at creating a flow cytometry platform for blood disorders.

The companies will use EMD Millipore's flow cytometry technology as a platform to accelerate the development of new diagnostic tools. If successful, they will then develop the platform for commercialization in the hematology space, EMD Millipore, division of Germany's Merck KGaA, said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.